Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MWN109 in Non-Diabetic Participants With Overweight or Obesity
NCT07791524Phase 2Completed
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd.
- Start
- Jan 2026
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MWN109 in obesity (5 arms), sponsored by Shanghai Minwei Biotechnology Co., Ltd. Primary endpoint: Percentage change in body weight compared to baseline at 20 weeks. Started Jan 2026; status: completed.
02
Drugs
MWN109
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07791524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07791524.